Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Vinayak, Shaveta; M. Tolaney, Sara; S. Schwartzberg, Lee; Mita, Monica; A. McCann, Georgia; R. Tan, Antoinette; E. Wahner-Hendrickson, Andrea; Forero, Andres; K. Anders, Carey; M. Wulf, Gerburg; M. Dillon, Patrick; Lynce, Filipa; Zarwan, Corrine; K. Erban, John; Zhou, Yinghui; Buerstatte, Nathan; R. Graham, Julie; Arora, Sujata; J. Dezube, Bruce; L. Telli, Melinda

doi:10.1001/jamaoncol.2019.1029

Public

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Published in JAMA Oncology • Jun 13, 2019

Authors:

Shaveta Vinayak

Sara M. Tolaney

Lee S. Schwartzberg

Abstract

IMPORTANCE: Poly(adenosine diphosphate-ribose) polymerase inhibitor and anti-programmed death receptor-1 inhibitor monotherapy have shown limited clinical activity in patients with advanced triple-negative breast cancer (TNBC). OBJECTIVE: To evaluate the clinical activity (primary) and safety (secon...

Subject

Medicine

Pembrolizumab

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!